Navigation Links
The Corporate Reputation of Pharma in 2012: The Patient Perspective on 29 of the World's Leading Pharma Companies
Date:11/28/2013

DUBLIN, November 28, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zm2pwl/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma in 2012: The Patient Perspective" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

A global survey of the views of 600 international, national, and regional patient groups on the corporate reputation of the pharma industry and 29 leading pharma companies

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients, recasting their companies as more patient-centric. PatientView is therefore pleased to ANNOUNCE THE RELEASE of the latest version of its annual review.

- A global survey, conducted mid-November to mid-December 2012, exploring the views of 600 international, national, and regional patient groups from 56 countries (72% from Europe) and differing specialties

- Patient group feedback on the corporate reputation of the pharma industry during 2012.

- Patient group feedback provides rankings of 29 leading pharma companies for six key indicators that influence corporate reputation: patient-centredness; patient information; patient safety; useful products; transparency; and integrity.

- Results for 2012 are compared with those of 2011.

This independent study, funded by PatientView, represents 600 patient groups' latest impressions on the corporate reputation of 29 individual pharma companies and of the pharma industry as a whole. Results for 2012 are compared with 2011. For the purposes of this report, the phrase 'corporate reputation' is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

Key findings industry-wide; reputation of pharma fell in 2012

The overall reputation of pharma declined in 2012. Only 34% of the 600 patient groups responding to the 2012 survey state that multinational pharma companies had an Excellent or Good reputation during 2012. The equivalent figure from the 500 patient groups responding to the 2011 survey was 42%. 40% of the 600 respondent patient groups state that the reputation of the pharma industry had declined during 2012. As many as 50% of the 600 respondent patient groups say that industry had a Poor record in 2012 for having fair pricing policies.48% of the 600 respondent patient groups say that industry had a Poor record in 2012 for being transparent.When the 2012 results are compared with those of 2011, the sharpest falls in pharma performance are for the following:

- Managing adverse news about producta 29% fall between 2011 and 2012.

- Having ethical marketing practicesa 23% fall between 2011 and 2012.

- Having a good relationship with the mediaa 19% fall, 2011-2012.

- Several reasons explain why pharma's reputation fell during 2012

Respondent patient groups report:

- a continuing failure to help patients in cash-strapped southern-European countries (such as Greece, Portugal, Romania, and Spain) gain access to medicines;

- a preoccupation by pharma with drugs that offer only short-term health benefits;

- not enough effort being made to discover chemical entities suitable for neglected catchments of patients;

- inappropriate marketing of drugs (including those for off-label indications);

- perceived lack of transparencyespecially in reporting the disappointing results of clinical trials;

- drugs prices that, in some cases, are still unaffordable to many patients or their payersculminating in a general impression that profit comes before making people well.

Companies Mentioned

- Abbott
- Allergan
- Amgen
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Eli Lilly (Lilly)
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Janssen
- Lundbeck
- Menarini
- Merck & Co (the US company)
- Merck Group (the German company)
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Servier
- Shire
- Stada Arzneimittel
- Takeda
- Teva
- UCB


For more information visit http://www.researchandmarkets.com/research/zm2pwl/the_corporate

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Survey Shows eContent Critical to Corporate Strategies
4. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
5. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
6. Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
7. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
8. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
9. InfuSystem Holdings Modifies Bylaws to Align with Corporate Governance Best Practices
10. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
11. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... ... 05, 2016 , ... Successful recruitment and retention efforts, new ... initiatives have all marked the last 12 months at Roswell Park Cancer Institute ... nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
Breaking Medicine News(10 mins):